Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IGN-311. Igeneon.

Hartmut Kristeleit1

  • 1Institute of Cancer Research, The Breakthrough Toby Robins Breast Cancer Research Center, 237 Fulham Road, London SW3 6JB, UK. Hartmut.Kristeleit@icr.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eribulin for the treatment of advanced breast cancer: A prospective observational registry study.

European journal of cancer care·2022
Same author

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study.

Oncology·2022
Same author

The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer Centre.

Cancers·2022
Same author

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.

Cancer cell·2021
Same author

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.

JAMA oncology·2019
Same author

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.

Cancer·2019

Igeneon is developing IGN-311, a humanized monoclonal antibody targeting the Lewis Y antigen, for cancer immunotherapy. This antibody shows potential for treating epithelial tumors in the breast, colon, gastric, and pancreatic tissues.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • The Lewis Y carbohydrate antigen is expressed on various epithelial tumors.
  • Monoclonal antibodies offer targeted therapeutic strategies in cancer treatment.

Purpose of the Study:

  • To evaluate IGN-311, a humanized monoclonal antibody, as a potential passive immunotherapy agent for cancer.
  • To investigate the efficacy of IGN-311 against epithelial tumors, including those in breast, colon, gastric, and pancreatic tissues.

Main Methods:

  • Development of IGN-311, a humanized monoclonal antibody targeting the Lewis Y antigen.
  • Administration of IGN-311 via intravenous infusion.
  • Initiation of a Phase I/II clinical trial in July 2005.

Main Results:

Related Experiment Videos

  • The abstract does not contain specific results from the trial.

Conclusions:

  • IGN-311 represents a potential novel therapeutic approach for epithelial cancers expressing the Lewis Y antigen.